Loading...

Buy Full Version
"Gene Therapy Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases): Global Opportunity Analysis and Industry Forecast, 2019–2026

LI_182841
Pages: 310
Dec 2019 | 12269 Views
 
Author(s) : Surabhi Pandey and Sumitra Choudhary , Onkar Sumant
Tables: 153
Charts: 56
 

Gene Therapy Market Outlook - 2026

The global gene therapy market size was valued at $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026.

Genes are composed of DNA that encodes necessary information for the synthesis of proteins that are vital for the human body to function optimally. Gene therapy is a technique in which DNA is introduced into a patient to treat genetic diseases. The new DNA contains a functioning gene to correct the effects of a disease, which causes mutations. 

Gene therapy involves repairing, repressing, or replacing dysfunctional genes that cause disease with the aim of reestablishing normal function. This therapy serves as a promising treatment option for some genetic diseases such as muscular dystrophy and cystic fibrosis as well as certain inherited disorders, cancer, and viral infections. In addition, it aids in drug development to identify the right target and approach, thereby addressing the root cause of severe diseases. In certain disorders where known genetic mutations lead to deficient or nonfunctional protein production, gene therapy can fix the underlying defect and provide a path to produce the functional protein. In addition, the risk of gene therapy is less, as a new gene introduced will integrate itself into the genome of the patient and continue functioning without hampering the operations of other genes. Hence, these aforementioned factors helps in increasing the global gene therapy market share.

Gene Therapy Market

Get more information on this report : Request Sample Pages

Gene therapies have brought a revolutionary change in the fields of health sciences and pharmaceuticals. Key players have adopted strategies such as product development and product launch to strengthen their foothold in the global market. For instance, in 2019, AveXis, a biotechnology company,  received a product approval for Zolgensma by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients with spinal muscular atrophy. Furthermore, in December 2017, Spark Therapeutics, Inc. receives an approval of Luxturna which is the first and only pharmacologic treatment for an inherited retinal disease. Moreover, increase in new pipeline developments for gene therapy was witnessed in 2018 as compared to previous years. Thus, the number of clinical trials, product launches, collaborations, and product developments is on the rise, which is expected to provide a lucrative opportunity for the growth of gene therapy market during the forecast period.

Increase in funding for R&D activities pertaining to gene therapy and rise in awareness regarding gene therapy are the major factors that drive the global gene therapy market growth. In addition, increase in government support for research in gene therapy, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer boost the growth of the gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the growth of the gene therapy market. On the contrary, untapped potential for emerging markets are expected to provide significant profitable opportunities for the manufacturers in the gene therapy industry.

Vector type segment review

On the basis of vector type, the market is categorized into viral vector and nonviral vector. Among these, the viral vector segment was the largest contributor toward the market growth in 2018, owing to easier modifications of many viruses such as Lentivirus, Adeno-Associated Virus (AAV), RetroVirus & Gamma RetroVirus to deliver gene therapy drugs, advancements on DNA, RNA and oncolytic viral vectors gene therapy. However, the nonviral vector segment is anticipated to exhibit fastest growth during the forecast period, due to advancements in physicochemical approaches such as physical methods and chemical methods of non-viral vector for gene therapies during preclinical and clinical trials for the treatment of various diseases.

Gene Therapy Market
By Vector Type

Your browser does not support the canvas element.

Viral Vector holds the dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Application segment review

The applications covered in the study include oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and others. The oncological disorders segment was the largest contributor toward the market growth in 2018, owing to increase in prevalence of cancer worldwide and increase in regulatory approval of gene therapy for cancer. However, the cardiovascular diseases segment is anticipated grow at a lucrative rate during the forecast period, due to increase in number of clinical trials of gene therapies for the treatment of these diseases.

Gene Therapy Market
By Application

Your browser does not support the canvas element.

Cardiovascular Diseases segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Region segment review

Region wise, the gene therapy market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the gene therapy market in 2018, and is anticipated to continue this trend during the forecast period, owing to high prevalence rate of cancer, presence of high disposable income, and increase in funding for R&D activities associated with gene therapy. However, Asia-Pacific is expected to register the highest growth during the forecast period, owing to rise in number of people prone to various chronic diseases. In addition, approval and launch of gene therapy products can positively influence market expansion in the developed countries, such as Japan, Australia, and New Zealand are the major factors for the growth of the gene therapy market. 

Gene Therapy Market
By Region

2026
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 45.4% during 2019-2026.

Get more information on this report : Request Sample Pages

The key players operating in the global gene therapy market include Adaptimmune Therapeutics Plc., Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc., Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc. Other prominent players in the value chain (companies not profiled in the report) includes Amgen, Epeius Biotechnologies, Sanofi, Juno Therapeutics, and Advantagene.

Key Benefits for Gene Therapy Market:

  • This report provides a detailed quantitative analysis of the current gene therapy market trends and gene therapy market forecast estimations from 2018 to 2026, which assists to identify the prevailing market opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • An in-depth gene therapy market analysis includes analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • The global gene therapy market is comprehensively analyzed with respect to type, method, technology, end user, and region.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
  • Region-wise and country-wise market conditions are comprehensively analyzed in this report.
  • Key players within the market are profiled in this report, and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the global market.

Gene Therapy Market Segments:

By Vector Type

  • Viral vector
    • Retroviruses
    • Lentiviruses
    • Adenoviruses
    • Adeno-associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Nonviral vector
    • Naked/Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others

By Gene Type

  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth factors
  • Receptors
  • Others

By Application

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
 

CHAPTER 1:  INTRODUCTION

1.1.  Report description
1.2.  Key benefits
1.3.  Key market segments
1.4.  Research methodology

1.4.1.  Secondary research
1.4.2.  Primary research
1.4.3.  Analyst tools and models

CHAPTER 2:  EXECUTIVE SUMMARY

2.1.  CXO perspective

CHAPTER 3:  MARKET OVERVIEW

3.1.  Market definition and scope
3.2.  Key findings

3.2.1.  Top investment pockets
3.2.2.  Top winning strategies

3.3.  Top player positioning, 2018
3.4.  Porter’s five forces analysis
3.5.  Market dynamics

3.5.1.  Drivers

3.5.1.1.  High investment for R&D activities pertaining to gene therapy
3.5.1.2.  Increase in prevalence of cancer
3.5.1.3.  Growth in awareness regarding gene therapy

3.5.2.  Restraints

3.5.2.1.  High cost associated with gene therapies
3.5.2.2.  Unwanted immune responses

3.5.3.  Opportunities

3.5.3.1.  Untapped potential for emerging markets

CHAPTER 4:  GENE THERAPY MARKET, BY VECTOR TYPE

4.1.  Overview

4.1.1.  Market size and forecast

4.2.  Viral vectors

4.2.1.  Key market trends, growth factors, and opportunities
4.2.2.  Market size and forecast, by region
4.2.3.  Market size and forecast, by type
4.2.4.  Market size and forecast, by country
4.2.5.  Adenovirus
4.2.6.  Lentivirus
4.2.7.  Retrovirus
4.2.8.  Adeno-associated virus
4.2.9.  Herpes simplex virus
4.2.10.  Poxvirus
4.2.11.  Vaccinia virus
4.2.12.  Others

4.3.  Non-viral Techniques

4.3.1.  Key market trends, growth factors, and opportunities
4.3.2.  Market size and forecast, by region
4.3.3.  Market size and forecast, by type
4.3.4.  Market size and forecast, by country
4.3.5.  Naked plasmid vector
4.3.6.  Gene gun
4.3.7.  Electroporation
4.3.8.  Lipofection
4.3.9.  Others

CHAPTER 5:  GENE THERAPY MARKET, BY GENE TYPE

5.1.  Overview

5.1.1.  Market size and forecast, type

5.2.  Antigen

5.2.1.  Market size and forecast
5.2.2.  Market size and forecast, by country

5.3.  Cytokine

5.3.1.  Market size and forecast
5.3.2.  Market size and forecast, by country

5.4.  Tumor suppressor

5.4.1.  Market size and forecast, by region
5.4.2.  Market size and forecast, by country

5.5.  Suicide Gene

5.5.1.  Market size and forecast
5.5.2.  Market size and forecast, by country

5.6.  Deficiency

5.6.1.  Market size and forecast, by region
5.6.2.  Market size and forecast, by country

5.7.  Growth factors

5.7.1.  Market size and forecast, by region
5.7.2.  Market size and forecast, by country

5.8.  Receptors

5.8.1.  Market size and forecast, by region
5.8.2.  Market size and forecast, by country

5.9.  Others

5.9.1.  Market size and forecast, by region
5.9.2.  Market size and forecast, by country

CHAPTER 6:  GENE THERAPY MARKET, BY APPLICATION

6.1.  Overview

6.1.1.  Market size and forecast, by application

6.2.  Oncological disorders

6.2.1.  Market size and forecast, by region
6.2.2.  Market size and forecast, by country

6.3.  Rare diseases

6.3.1.  Market size and forecast, by region
6.3.2.  Market size and forecast, by country

6.4.  Cardiovascular diseases

6.4.1.  Market size and forecast, by region
6.4.2.  Market size and forecast, by country

6.5.  Neurological disorders

6.5.1.  Market size and forecast
6.5.2.  Market size and forecast, by country

6.6.  Infectious diseases

6.6.1.  Market size and forecast, by region
6.6.2.  Market size and forecast, by country

6.7.  Other diseases

6.7.1.  Market size and forecast
6.7.2.  Market size and forecast, by country

CHAPTER 7:  GENE THERAPY MARKET, BY REGION

7.1.  Overview

7.1.1.  Market size and forecast

7.2.  North America

7.2.1.  Key market trends, growth factors, and opportunities
7.2.2.  Market size and forecast, by country
7.2.3.  Market size and forecast, by vector type
7.2.4.  Market size and forecast, by gene type
7.2.5.  Market size and forecast, by application

7.2.5.1.  U.S. market size and forecast, by vector type
7.2.5.2.  U.S. market size and forecast, by gene type
7.2.5.3.  U.S. market size and forecast, by application
7.2.5.4.  Canada market size and forecast, by vector type
7.2.5.5.  Canada market size and forecast, by gene type
7.2.5.6.  Canada market size and forecast, by application
7.2.5.7.  Mexico market size and forecast, by vector type
7.2.5.8.  Mexico market size and forecast, by gene type
7.2.5.9.  Mexico market size and forecast, by application

7.3.  Europe

7.3.1.  Key market trends, growth factors, and opportunities
7.3.2.  Market size and forecast, by country
7.3.3.  Market size and forecast, by vector type
7.3.4.  Market size and forecast, by gene type
7.3.5.  Market size and forecast, by application

7.3.5.1.  Germany market size and forecast, by vector type
7.3.5.2.  Germany market size and forecast, by gene type
7.3.5.3.  Germany market size and forecast, by application
7.3.5.4.  France market size and forecast, by vector type
7.3.5.5.  France market size and forecast, by gene type
7.3.5.6.  France market size and forecast, by application
7.3.5.7.  UK market size and forecast, by vector type
7.3.5.8.  UK market size and forecast, by gene type
7.3.5.9.  UK market size and forecast, by application
7.3.5.10.  Italy market size and forecast, by vector type
7.3.5.11.  Italy market size and forecast, by gene type
7.3.5.12.  Italy market size and forecast, by application
7.3.5.13.  Spain market size and forecast, by vector type
7.3.5.14.  Spain market size and forecast, by gene type
7.3.5.15.  Spain market size and forecast, by application
7.3.5.16.  Rest of Europe market size and forecast, by vector type
7.3.5.17.  Rest of Europe market size and forecast, by gene type
7.3.5.18.  Rest of Europe market size and forecast, by application

7.4.  Asia-Pacific

7.4.1.  Key market trends, growth factors, and opportunities
7.4.2.  Market size and forecast, by country
7.4.3.  Market size and forecast, by vector type
7.4.4.  Market size and forecast, by gene type
7.4.5.  Market size and forecast, by application

7.4.5.1.  Japan market size and forecast, by vector type
7.4.5.2.  Japan market size and forecast, by gene type
7.4.5.3.  Japan market size and forecast, by application
7.4.5.4.  China market size and forecast, by vector type
7.4.5.5.  China market size and forecast, by gene type
7.4.5.6.  China market size and forecast, by application
7.4.5.7.  India market size and forecast, by vector type
7.4.5.8.  India market size and forecast, by gene type
7.4.5.9.  India market size and forecast, by application
7.4.5.10.  South Korea market size and forecast, by vector type
7.4.5.11.  South Korea market size and forecast, by gene type
7.4.5.12.  South Korea market size and forecast, by application
7.4.5.13.  Rest of Asia-Pacific market size and forecast, by vector type
7.4.5.14.  Rest of Asia-Pacific market size and forecast, by gene type
7.4.5.15.  Rest of Asia-Pacific market size and forecast, by application

7.5.  LAMEA

7.5.1.  Key market trends, growth factors, and opportunities
7.5.2.  Market size and forecast, by country
7.5.3.  Market size and forecast, by vector type
7.5.4.  Market size and forecast, by gene type
7.5.5.  Market size and forecast, by application

7.5.5.1.  Brazil market size and forecast, by vector type
7.5.5.2.  Brazil market size and forecast, by gene type
7.5.5.3.  Brazil market size and forecast, by application
7.5.5.4.  South Africa market size and forecast, by vector type
7.5.5.5.  South Africa market size and forecast, by gene type
7.5.5.6.  South Africa market size and forecast, by application
7.5.5.7.  Rest of LAMEA market size and forecast, by vector type
7.5.5.8.  Rest of LAMEA market size and forecast, by gene type
7.5.5.9.  Rest of LAMEA market size and forecast, by application

CHAPTER 8:  COMPANY PROFILE

8.1.  ADAPTIMMUNE THERAPEUTICS PLC.

8.1.1.  Company overview
8.1.2.  Company snapshot
8.1.3.  Operating business segments
8.1.4.  Product portfolio
8.1.5.  Business performance
8.1.6.  Key strategic moves and developments

8.2.  ANCHIANO THERAPEUTICS LTD.

8.2.1.  Company overview
8.2.2.  Company snapshot
8.2.3.  Operating business segments
8.2.4.  Product portfolio

8.3.  ACHIEVE LIFE SCIENCES, INC.

8.3.1.  Company overview
8.3.2.  Company snapshot
8.3.3.  Operating business segments
8.3.4.  Product portfolio
8.3.5.  Key strategic moves and developments

8.4.  ADVERUM BIOTECHNOLOGIES, INC.

8.4.1.  Company overview
8.4.2.  Company snapshot
8.4.3.  Operating business segments
8.4.4.  Product portfolio
8.4.5.  Key strategic moves and developments

8.5.  ABEONA THERAPEUTICS INC.

8.5.1.  Company overview
8.5.2.  Company snapshot
8.5.3.  Operating business segments
8.5.4.  Product portfolio
8.5.5.  Business performance
8.5.6.  Key strategic moves and developments

8.6.  APPLIED GENETIC TECHNOLOGIES CORPORATION

8.6.1.  Company overview
8.6.2.  Company snapshot
8.6.3.  Operating business segments
8.6.4.  Product portfolio
8.6.5.  Business performance
8.6.6.  Key strategic moves and developments

8.7.  ARBUTUS BIOPHARMA CORPORATION

8.7.1.  Company overview
8.7.2.  Company snapshot
8.7.3.  Product portfolio
8.7.4.  Business performance
8.7.5.  Key strategic moves and developments

8.8.  AUDENTES THERAPEUTICS INC.

8.8.1.  Company overview
8.8.2.  Company snapshot
8.8.3.  Product portfolio
8.8.4.  Key strategic moves and developments

8.9.  AVEXIS INC.

8.9.1.  Company overview
8.9.2.  Company snapshot
8.9.3.  Product portfolio
8.9.4.  Key strategic moves and developments

8.10.  BLUEBIRD BIO, INC.

8.10.1.  Company overview
8.10.2.  Company snapshot
8.10.3.  Operating business segments
8.10.4.  Product portfolio
8.10.5.  Business performance
8.10.6.  Key strategic moves and developments

8.11.  CELGENE CORPORATION

8.11.1.  Company overview
8.11.2.  Company snapshot
8.11.3.  Operating business segments
8.11.4.  Product portfolio
8.11.5.  Business performance
8.11.6.  Key strategic moves and developments

8.12.  CRISPR THERAPEUTICS AG

8.12.1.  Company overview
8.12.2.  Company snapshot
8.12.3.  Product portfolio
8.12.4.  Business performance
8.12.5.  Key strategic moves and developments

8.13.  EDITAS MEDICINE, INC.

8.13.1.  Company overview
8.13.2.  Company snapshot
8.13.3.  Operating business segments
8.13.4.  Product portfolio
8.13.5.  Business performance
8.13.6.  Key strategic moves and developments

8.14.  GILEAD SCIENCES, INC.

8.14.1.  Company overview
8.14.2.  Company snapshot
8.14.3.  Operating business segments
8.14.4.  Product portfolio
8.14.5.  Business performance
8.14.6.  Key strategic moves and developments

8.15.  GLAXOSMITHKLINE PLC

8.15.1.  Company overview
8.15.2.  Company snapshot
8.15.3.  Operating business segments
8.15.4.  Product portfolio
8.15.5.  Business performance
8.15.6.  Key strategic moves and developments

8.16.  INTELLIA THERAPEUTICS INC.

8.16.1.  Company overview
8.16.2.  Company snapshot
8.16.3.  Operating business segments
8.16.4.  Product portfolio
8.16.5.  Business performance
8.16.6.  Key strategic moves and developments

8.17.  MERCK & CO., INC.

8.17.1.  Company overview
8.17.2.  Company snapshot
8.17.3.  Operating business segments
8.17.4.  Product portfolio
8.17.5.  Business performance
8.17.6.  Key strategic moves and developments

8.18.  NOVARTIS AG

8.18.1.  Company overview
8.18.2.  Company snapshot
8.18.3.  Operating business segments
8.18.4.  Product portfolio
8.18.5.  Business performance
8.18.6.  Key strategic moves and developments

8.19.  REGENXBIO, INC.

8.19.1.  Company overview
8.19.2.  Company snapshot
8.19.3.  Product portfolio
8.19.4.  Business performance
8.19.5.  Key strategic moves and developments

8.20.  SPARK THERAPEUTICS, INC.

8.20.1.  Company overview
8.20.2.  Company snapshot
8.20.3.  Operating business segments
8.20.4.  Product portfolio
8.20.5.  Business performance
8.20.6.  Key strategic moves and developments

8.21.  SANGAMO THERAPEUTICS, INC.

8.21.1.  Company overview
8.21.2.  Company snapshot
8.21.3.  Operating business segments
8.21.4.  Product portfolio
8.21.5.  Business performance
8.21.6.  Key strategic moves and developments

8.22.  UNIQURE N. V.

8.22.1.  Company overview
8.22.2.  Company snapshot
8.22.3.  Operation segments
8.22.4.  Product portfolio
8.22.5.  Business performance
8.22.6.  Key strategic moves and developments

8.23.  VOYAGER THERAPEUTICS, INC.

8.23.1.  Company overview
8.23.2.  Company snapshot
8.23.3.  Operating business segments
8.23.4.  Product portfolio
8.23.5.  Business performance
8.23.6.  Key strategic moves and developments

LIST OF TABLES

TABLE 01.  LATE-STAGE CLINICAL DATA EVENTS OF GENE THERPY
TABLE 02.  GENE THERAPY PIPELINE VOLUME, PRECLINICAL THROUGH PRE-REGISTRATION PHASE, 1995–2018
TABLE 03.  GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 04.  GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2018–2026 ($MILLION)
TABLE 05.  GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2018–2026 ($MILLION)
TABLE 06.  GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION, 2018–2026 ($MILLION)
TABLE 07.  GLOBAL GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2018–2026 ($MILLION)
TABLE 08.  GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 09.  ANTIGEN GENE THERAPY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10.  CYTOKINE GENE THERAPY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11.  TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 12.  SUICIDE GENE THERAPY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 13.  DEFICIENCY GENE THERAPY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 14.  GROWTH FACTORS GENE THERAPY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 15.  RECEPTORS GENE THERAPY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 16.  GENE THERAPY MARKET FOR OTHER GENE TYPES, BY REGION, 2018–2026 ($MILLION)
TABLE 17.  GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 18.  GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, BY REGION, 2018–2026 ($MILLION)
TABLE 19.  GENE THERAPY MARKET FOR RARE DISEASES, BY REGION, 2018–2026 ($MILLION)
TABLE 20.  GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018–2026 ($MILLION)
TABLE 21.  GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2018–2026 ($MILLION)
TABLE 22.  GENE THERAPY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2026 ($MILLION)
TABLE 23.  GENE THERAPY MARKET FOR OTHER DISEASES, BY REGION, 2018–2026 ($MILLION)
TABLE 24.  GENE THERAPY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 25.  NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 26.  NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 27.  NORTH AMERICA GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 28.  NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 29.  U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 30.  U.S. GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 31.  U.S. GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 32.  CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 33.  CANADA GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 34.  CANADA GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 35.  MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 36.  MEXICO GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 37.  MEXICO GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 38.  EUROPE GENE THERAPY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 39.  EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 40.  EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 41.  EUROPE GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 42.  GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 43.  GERMANY GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 44.  GERMANY GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 45.  FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 46.  FRANCE GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 47.  FRANCE GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 48.  UK GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 49.  UK GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 50.  UK GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 51.  ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 52.  ITALY GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 53.  ITALY GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 54.  SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 55.  SPAIN GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 56.  SPAIN GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 57.  REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 58.  REST OF EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 59.  REST OF EUROPE GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 60.  ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 61.  ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 62.  ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 63.  ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 64.  JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 65.  JAPAN GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 66.  JAPAN GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 67.  CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 68.  CHINA GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 69.  CHINA GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 70.  INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 71.  INDIA GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 72.  INDIA GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 73.  SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 74.  SOUTH KOREA GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 75.  SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 76.  REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 77.  REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 78.  REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 79.  LAMEA GENE THERAPY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 80.  LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 81.  LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 82.  LAMEA GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 83.  BRAZIL GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 84.  BRAZIL GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 85.  BRAZIL GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 86.  SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 87.  SOUTH AFRICA GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 88.  SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 89.  REST OF LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2018–2026 ($MILLION)
TABLE 90.  REST OF LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2018–2026 ($MILLION)
TABLE 91.  REST OF LAMEA GENE THERAPY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 92.  ADAPTIMMUNE: COMPANY SNAPSHOT
TABLE 93.  ADAPTIMMUNE: BUSINESS UNIT
TABLE 94.  ADAPTIMMUNE.: PRODUCT PORTFOLIO
TABLE 95.  ANCHIANO THERAPEUTICS: COMPANY SNAPSHOT
TABLE 96.  ANCHIANO THERAPEUTICS: PRODUCT CATEGORY
TABLE 97.  ANCHIANO THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 98.  ACHIEVE LIFE SCIENCES.: COMPANY SNAPSHOT
TABLE 99.  ACHIEVE LIFE SCIENCES.: OPERATING SEGMENTS
TABLE 100.  ACHIEVE LIFE SCIENCES: PRODUCT PORTFOLIO
TABLE 101.  ADVERUM BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 102.  ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT CATEGORY
TABLE 103.  ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 104.  ABEONA THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE 105.  ABEONA THERAPEUTICS INC.: PRODUCT CATEGORY
TABLE 106.  ABEONA THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE 107.  APPLIED GENETIC TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT
TABLE 108.  APPLIED GENETIC TECHNOLOGIES CORPORATION: OPERATING SEGMENTS
TABLE 109.  APPLIED GENETIC TECHNOLOGIES CORPORATION: PRODUCT PORTFOLIO
TABLE 110.  ARBUTUS: COMPANY SNAPSHOT
TABLE 111.  ARBUTUS: PRODUCT PORTFOLIO
TABLE 112.  AUDENTES: COMPANY SNAPSHOT
TABLE 113.  AUDENTES: PRODUCT PORTFOLIO
TABLE 114.  AVEXIS: COMPANY SNAPSHOT
TABLE 115.  AVEXIS: PRODUCT PORTFOLIO
TABLE 116.  BLUEBIRD BIO : COMPANY SNAPSHOT
TABLE 117.  BLUEBIRD BIO: PRODUCT CATEGORY
TABLE 118.  BLUEBIRD BIO.: PRODUCT PORTFOLIO
TABLE 119.  CELGENE: COMPANY SNAPSHOT
TABLE 120.  CELGENE: OPERATING SEGMENTS
TABLE 121.  CELGENE: PRODUCT PORTFOLIO
TABLE 122.  CRISPR: COMPANY SNAPSHOT
TABLE 123.  CRISPR: PRODUCT PORTFOLIO
TABLE 124.  EDITAS.: COMPANY SNAPSHOT
TABLE 125.  EDITAS: PRODUCT PORTFOLIO
TABLE 126.  GILEAD: COMPANY SNAPSHOT
TABLE 127.  GILEAD: OPERATING SEGMENTS
TABLE 128.  GILEAD: PRODUCT PORTFOLIO
TABLE 129.  GSK.: COMPANY SNAPSHOT
TABLE 130.  GSK: OPERATING SEGMENTS
TABLE 131.  GSK: PRODUCT PORTFOLIO
TABLE 132.  INTELLIA: COMPANY SNAPSHOT
TABLE 133.  INTELLIA: PRODUCT PORTFOLIO
TABLE 134.  MERCK: COMPANY SNAPSHOT
TABLE 135.  MERCK: OPERATING SEGMENTS
TABLE 136.  MERCK.: PRODUCT PORTFOLIO
TABLE 137.  NOVARTIS: COMPANY SNAPSHOT
TABLE 138.  NOVARTIS: OPERATING DIVISION
TABLE 139.  NOVARTIS: PRODUCT PORTFOLIO
TABLE 140.  REGENXBIO: COMPANY SNAPSHOT
TABLE 141.  REGENXBIO: PRODUCT PORTFOLIO
TABLE 142.  SPARK THERAPEUTICS: COMPANY SNAPSHOT
TABLE 143.  SPARK THERAPEUTICS, INC.: PRODUCT CATEGORY
TABLE 144.  SPARK THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 145.  SANGAMO THERAPEUTICS: COMPANY SNAPSHOT
TABLE 146.  SANGAMO THERAPEUTICS: OPERATING BUSINESS SEGMENTS
TABLE 147.  SANGAMO THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 148.  UNIQURE: COMPANY SNAPSHOT
TABLE 149.  UNIQURE: PRODUCT BUSINESS SEGMENT
TABLE 150.  UNIQURE.: PRODUCT PORTFOLIO
TABLE 151.  VOYAGER.: COMPANY SNAPSHOT
TABLE 152.  VOYAGER : PRODUCT BUSINESS SEGMENTS
TABLE 153.  VOYAGER.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.  GLOBAL GENE THERAPY MARKET SEGMENTATION
FIGURE 02.  TOP INVESTMENT POCKETS: BY GENE TYPE, 2018
FIGURE 03.  TOP WINNING STRATEGIES, BY YEAR, 2016–2019*
FIGURE 04.  TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2019* (%)
FIGURE 05.  TOP WINNING STRATEGIES, BY COMPANY, 2016–2019*
FIGURE 06.  TOP PLAYER POSITIONING, 2018
FIGURE 07.  LOW BARGAINING POWER OF BUYERS
FIGURE 08.  HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 09.  HIGH THREAT OF NEW ENTRANTS
FIGURE 10.  MODERATE THREAT OF SUBSTITUTION
FIGURE 11.  HIGH COMPETITIVE RIVALRY
FIGURE 12.  RESTRAINTS AND DRIVERS: GLOBAL GENE THERAPY MARKET
FIGURE 13.  COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR VIRAL VECTORS, 2018 VS 2026 ($MILLION)
FIGURE 14.  COMPARATIVE ANALYSIS OF GENE THERAPY MARKET FOR NON-VIRAL VECTORS, 2018 VS 2026 (%)
FIGURE 15.  COMPARATIVE ANALYSIS OF ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2018 VS 2026 (%)
FIGURE 16.  COMPARATIVE ANALYSIS OF CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2018 VS 2026 (%)
FIGURE 17.  COMPARATIVE ANALYSIS OF TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2018 VS 2026 (%)
FIGURE 18.  COMPARATIVE ANALYSIS OF SUICIDE GENE THERAPY MARKET, BY COUNTRY, 2018 VS 2026 (%)
FIGURE 19.  COMPARATIVE ANALYSIS OF DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2018 VS 2026 (%)
FIGURE 20.  COMPARATIVE ANALYSIS OF GROWTH FACTORS GENE THERAPY MARKET, BY COUNTRY, 2018 VS 2026(%)
FIGURE 21.  COMPARATIVE ANALYSIS OF RECEPTORS GENE THERAPY MARKET, BY COUNTRY, 2018 VS 2026 (%)
FIGURE 22.  COMPARATIVE ANALYSIS OF GENE THERAPY MARKET FOR OTHER GENE TYPES, 2018 VS 2026 (%)
FIGURE 23.  COMPARATIVE ANALYSIS OF GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, 2018 VS 2026 (%)
FIGURE 24.  COMPARATIVE ANALYSIS OF GENE THERAPY MARKET FOR RARE DISEASES, 2018 VS 2026 (%)
FIGURE 25.  COMPARATIVE ANALYSIS OF GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, 2018 VS 2026 (%)
FIGURE 26.  COMPARATIVE ANALYSIS OF GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, 2018 VS 2026 (%)
FIGURE 27.  COMPARATIVE ANALYSIS OF GENE THERAPY MARKET FOR INFECTIOUS DISEASES, 2018 VS 2026 (%)
FIGURE 28.  COMPARATIVE ANALYSIS OF GENE THERAPY MARKET FOR OTHER DISEASES, 2018 VS 2026 (%)
FIGURE 29.  ADAPTIMMUNE: REVENUE, 2016-2018($MILLION)
FIGURE 30.  ADAPTIMMUNE: SEGMENTATION, 2016-2018(%)
FIGURE 31.  ABEONA THERAPEUTICS INC.: NET SALES, 2014–2016 ($MILLION)
FIGURE 32.  APPLIED GENETIC TECHNOLOGIES CORPORATION: NET SALES, 2015–2017 ($MILLION)
FIGURE 33.  ARBUTUS: NET SALES, 2016–2018 ($MILLION)
FIGURE 34.  BLUEBIRD BIO: REVENUE, 2016-2018($MILLION)
FIGURE 35.  CELGENE: REVENUE, 2016-2018($MILLION)
FIGURE 36.  CELGENE: REVENUE SHARE BY PRODUCT, 2018 (%)
FIGURE 37.  CELGENE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 38.  CRISPR: NET SALES, 2016–2018 ($MILLION)
FIGURE 39.  EDITAS: NET SALES, 2016–2018 ($MILLION)
FIGURE 40.  GILEAD: REVENUE, 2016-2018($MILLION)
FIGURE 41.  GILEAD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42.  GSK: REVENUE, 2016-2018($MILLION)
FIGURE 43.  GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44.  GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 45.  INTELLIA: NET SALES, 2016–2018 ($MILLION)
FIGURE 46.  MERCK: REVENUE, 2016-2018($MILLION)
FIGURE 47.  MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 48.  MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 49.  NOVARTIS: REVENUE, 2016–2018 ($MILLION)
FIGURE 50.  NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 51.  NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 52.  REGENXBIO: NET SALES, 2016–2018 ($MILLION)
FIGURE 53.  SPARK THERAPEUTICS, INC.: REVENUE, 2016–2018 ($MILLION)
FIGURE 54.  SANGAMO THERAPEUTICS: NET SALES, 2016–2018 ($MILLION)
FIGURE 55.  UNIQURE.: NET SALES, 2016–2018 ($MILLION)
FIGURE 56.  VOYAGER: NET SALES, 2016–2018 ($MILLION)

 
 

Over the recent years, the demand for gene therapy is on a rapid increase. With the advancement in technology, the gene therapy market has transformed during the recent few years. Gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Due to the high success rate during the preclinical and clinical trial, gene therapy is gaining popularity. There are many techniques used for gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal. 

The employment of gene therapy is highest in North America in 2018, owing to the increase in funding for the R&D activities, high prevalence rate of cancer, and increase in disposable income among customers. Although the use of gene therapy in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase due to rise in disposable income, rise in incidence rate of cancer, large number of clinical trials being conducted in these regions, and government initiative to improve healthcare infrastructure, which in turn fuel the market growth.
 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Gene Therapy Market

  • Online Only
  • $3,456  $3,041
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,379
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370  $4,296
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $4,838
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995  $6,297
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Access
  • $0.00
  • Published Content E-Access
  • Company Profiles E-Access
  • Newly Added Content Access
  • 10 PDF Downloads
  • 5 Excel Data Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly
    ,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample